Objectives: There is an urgent need for accurate and fast diagnostic tests to identify carbapenemase-producing bacteria. Here, we have evaluated three MALDI-TOF-based techniques to detect carbapenemase-producing Enterobacteriaceae (CPE) from cultured colonies.
Introduction
Currently, the increase of carbapenem resistance in Gram-negative bacilli is of great concern worldwide. 1 Carbapenem resistance is mediated by two main processes: (i) association of decreased outermembrane permeability with plasmid-encoded or chromosomeencoded cephalosporinases and/or ESBLs; and (ii) production of carbapenem-hydrolysing enzymes (carbapenemases). 2 In Enterobacteriaceae, the rise of resistance to carbapenems is mainly due to the dissemination of carbapenemase producers, which are often resistant to most, if not all, antimicrobial molecules available.
The carbapenemases belong to three groups according to the Ambler classification: (i) Ambler Class A carbapenemases including mostly KPC enzymes but also rarer enzymes such as IMI, NMC-A, SME, some GES variants and FRI-1; [3] [4] [5] (ii) Ambler Class B MBLs with NDM-, VIM-, IMP-and GIM-types; 6 and (iii) carbapenem-hydrolysing Ambler Class D b-lactamases (CHDL) of the OXA-48 group (mostly OXA-48, OXA-162, OXA-181, OXA-204, OXA-232, OXA-244 and OXA-245). 7 To fight the dissemination of carbapenemaseproducing Enterobacteriaceae (CPE), their early detection is one of the key issues. Unfortunately, classic antibiotic susceptibility testing is not totally effective for the detection of CPE. Even with low screening cut-offs defined by EUCAST (MIC 0.125 mg/L for meropenem or ertapenem and 1 mg/L for imipenem) nearly 20% of CPEs are missed, especially OXA-48 producers. 8 Recently, two algorithms based on recording the inhibition diameter around discs for a few (two or three) antibiotics were proposed to directly identify non-CPE among carbapenem-resistant Enterobacteriaceae. 9, 10 However, 42% to 66% of Enterobacteriaceae with reduced susceptibility to at least one carbapenem required confirmatory testing. Thus, simple and reliable confirmatory tests are mandatory to rapidly discriminate CPE from non-CPE. 11 Various phenotypic confirmation tests for detecting carbapenemases have been developed, including inhibition tests of carbapenemase activity, 11, 12 the modified Hodge test 13 and the Carbapenem Inactivation Method. 14, 15 These tests are cheap but they require at least 16 h of additional incubation time after antimicrobial susceptibility results and often lack sensitivity and specificity (mostly the case for inhibition tests and the modified Hodge test). Immunochromatographic assays, aiming to detect OXA-48-like CPE, 16, 17 20 However, to be really useful these immunochromatographic assays need to be able to detect all the most common carbapenemases including VIM, which is still not possible. Molecular methods are still considered the gold standard for the detection of carbapenemase producers, [21] [22] [23] despite the fact that they regularly misidentify several OXA-48 variants (i.e. OXA-163 and OXA-405) that are not true carbapenemases. 9, 24 The detection of carbapenem-hydrolysing activity remains the most powerful method to detect all types of carbapenemases including those considered to be rare (e.g. IMI, GES, FRI, DIM, GIM, AIM, etc.) and therefore not included in commercially available molecular tests. 21, 22 These tests include biochemical tests (e.g. Carba NP Test and derivatives) [24] [25] [26] and MALDI-TOF MS techniques. 27 All published MALDI-TOF MS assays are based on the same principle that aims to detect the disappearance of the native carbapenem and/or the production of the carbapenem hydrolysis product after incubation of the tested strain with a carbapenem molecule. Currently, all these techniques are based on in-house protocols that use different carbapenem molecules such as imipenem, meropenem or ertapenem; different bacterial inocula; and variable incubation times from 20 min to 4 h. These protocols are difficult to standardize and, to our knowledge, no comparison has been performed between MALDI-TOF MS techniques using the same collection of strains.
Here, we have compared the performance of two in-house assays with the first CE-IVD (in vitro diagnostic)-certified mass spectrometric resistance detection assay (MBT STAR V R -Carba IVD Kit in conjunction with the MBT STAR V R -BL IVD software, Bruker Daltonics; MBT STAR V R being MALDI Biotyper Selective Testing of Antibiotic Resistance) for the rapid detection of CPE. In addition, we have assessed the repeatability of the MBT STAR V R -Carba IVD Kit. 
Materials and methods

Strain collection and participating centres
Antimicrobial susceptibility testing
MICs of carbapenems were previously determined using the Etest V R (bioMérieux) 21, 24 and results were recorded according to EUCAST guidelines.
In-house MALDI-TOF-based assays
The Brest in-house MALDI-TOF-based assay was performed in the microbiology unit of the University Hospital of Brest (Brest, France) as previously published. 28 Briefly, a 1 lL loopful of bacteria was suspended in 20 lL of 0.5 mg/mL imipenem solution, incubated for 20 min at 37 C and centrifuged for 1 min at 14 000 g. 28 and strains were classified as carbapenemase producers when this ratio was greater than or equal to the cut-off.
The Colmar in-house MALDI-TOF-based assay was performed in the microbiology unit of the Colmar Civil Hospitals (Colmar, France) as follows: ready-to-use 1 mL aliquots of imipenem/cilastatin 0.5 mg/mL solution were prepared with commercially available drug (MYLAN V R , France) diluted in sterile 0.45% NaCl (Versylène V R Fresenius, France). Aliquots were stored at #80
C. Blinded strains were incubated overnight on blood agar plates (bioMérieux, France) at 35 C. A 10 lL loopful of bacteria was suspended in an imipenem solution aliquot, vortexed for 15 s and incubated for 1-2 h at 35 C, then centrifuged for 2 min at 12 000 g. One microlitre of the supernatant was spotted in duplicate onto a FlexiMass target plate (bioMérieux, France) and overlaid with 1 lL of HCCA matrix before drying at room temperature. Mass spectra acquisitions were performed using a VITEK V R MS Plus Research Use Only (RUO) instrument (bioMérieux, France) and Shimadzu Biotech Launchpad v2.9 (Shimadzu Corporation, Japan), in positive linear ion mode between 150 and 650 m/z and optimal pulsed extraction at 400 m/z. Final analysed spectra were obtained by the superposition of five shots on 100 points per spot. The matrix [2HCCA ! H ! ] peak at 379 m/z was used for calibration. 29 The strains for which a total disappearance of native imipenem peak at 302 m/z and/or adduct [imipenem ! HCCA] peak at 489 m/z was observed after 1 h of incubation were considered as producing carbapenemase (Figure 1b) . 30 Analyses were repeated with 2 h incubation using the same interpretation criteria for all strains negative after 1 h. -producing E. coli (strain 25), KPC-2-producing E. coli (strain 2), NDM-1-producing E. coli (strain 6), GIM-1-produing E. cloacae (strain 20), OXA-48-producing E. cloacae (strain 143), OXA-48-producing E. coli (strain 64), OXA-181-producing E. coli (strain 30), imipenem alone, VIM-1-producing Klebsiella pneumoniae (strain 62), KPC-3-producing K. pneumoniae (strain 105) and OXA-48-producing K. pneumoniae (strain 122). This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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MBT STAR
V R -Carba IVD Kit
The MBT STAR V R -Carba IVD Kit testing was performed in the bacteriology unit of the Bicêtre hospital as recommended by the manufacturer. Briefly, 50 lL of MBT STAR V R -BL incubation buffer was added into a ready-to-use tube containing MBT STAR V R -BL antibiotic reagent. One to five individual bacterial colonies were resuspended in the tube by vortexing. Samples were incubated at 37 C for 30 min under agitation (900 rpm). After incubation, the bacteria were pelleted by centrifugation for 2 min at 16 000 g. One microlitre of the supernatant was loaded onto the MALDI target, dried under a stream of air (1 min) and overlaid with the MBT STAR V R -BL Matrix solution. The spots were dried gently under a stream of air (,1 min). MALDI-TOF MS analysis was performed on the Microflex LT Biotyper mass spectrometer (Bruker Daltonics). Final spectra were automatically interpreted using the MBT STAR V R -BL IVD software. Results can be visualized as a graphic (Figure 1c) or as a table ( Figure S1 ).
RAPIDEC
V R CARBA NP
The RAPIDEC V R CARBA NP testing was performed as previously described, 24, 25 using an increased inoculum of bacteria compared with the manufacturer's recommendations. During this evaluation, results were checked and interpreted at 5, 15, 30, 60 and 120 min of incubation in the revealing reagent (phenol red) after the first step of bacterial lysis (30 min).
Performance calculation
Sensitivity, specificity and positive and negative predictive values were computed using the free software vassarStats (http://vassarstats.net/). Repeatability was evaluated using the Cohen's unweighted kappa score as a measure of inter-rater agreement for qualitative (categorical) items. 31 Calculation of the Cohen's unweighted kappa score was performed using the vassarStats software. The kappa score was interpreted as follows: 0, poor agreement; 0.01-0.20, slight agreement; 0.21-0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; 0.81-1, almost perfect agreement. 32 
Results
Comparison of the performances of the three MALDI-TOF techniques for the detection of carbapenemaseproducing Enterobacteriaceae
Results of the three MALDI-TOF techniques for each tested strain are summarized in Tables S1 to S4. Overall, these three MALDI-TOF techniques possessed good sensitivity and specificity for the identification of CPE among Enterobacteriaceae with decreased susceptibility to carbapenems. The performances ranged from 95.0% to 100% sensitivity and 98.2% to 100% specificity (Table 1) . These performances were similar to those of the RAPIDEC V R CARBA NP which had 99.2% sensitivity and 100% specificity. On this strain collection, the Brest in-house MALDI-TOF technique was the most efficient technique with 100% sensitivity and 100% specificity (Table 1) . Both MALDI-TOF techniques performed on the Microflex LT Biotyper (Bruker) instrument possessed 100% sensitivity, while the Colmar in-house technique performed on the VITEK V R MS Plus failed to identify six CPE including two NDM-1 producers (Table S3) and four OXA-48 variants (two OXA-232 producers and two OXA-244 producers) (Table S4 ). Of note, OXA-232 and OXA-244 enzymes were described to have weak hydrolysis activity compared with OXA-48. [33] [34] [35] Accordingly, and as previously observed, the RAPIDEC V R CARBA NP also failed to detect one of the OXA-244 producers (Table S4) . 24, 33 The two NDM-1 producers that were not detected by the Colmar in-house technique belong to the Proteeae family (Providencia stuartii and Providencia rettgeri). In these two strains the bla NDM-1 gene is present as a single copy located on the chromosome. 36 The MBT STAR V R -Carba IVD Kit was not able to correctly identify one non-CPE (Table S1 ) leading to a specificity of 98.2%. This non-CPE strain, an Enterobacter cloacae isolate with decreased susceptibility related to overexpression of its chromosome-encoded AmpC associated with outer-membrane impermeability, gave a doubtful result with a ratio of 0.22. When this strain was tested again, ratios of 0.28 and 0.34, both assigned as doubtful, were obtained (Table S5) .
Regarding the characteristics of the three MALDI-TOF methods and the RAPIDEC V R CARBA NP, the MBT STAR V R -Carba IVD Kit is the only one which can provide concomitant identification of the bacterial isolate.
Repeatability of the commercially available MBT STAR
V RCarba IVD Kit
As the MBT STAR V R -Carba IVD Kit is the only commercially available MALDI-TOF-based assay, we evaluated its repeatability. Accordingly, for each strain the test was performed three times by the same technician with a gap of 7 days between each repetition. As shown in Table S5 , the same classification (CPE, non-CPE or doubtful result) was obtained for all strains except one ACC-1-producing Escherichia coli (strain 23), which was classified twice as non-CPE and once as doubtful, and one OXA-244-producing E. coli (strain 33), which was classified twice as CPE and once as non-CPE. Overall, a calculated kappa coefficient of 0.987 (95% CI 0.961-1.000) demonstrated an almost perfect repeatability of the technique.
Comparison of the turnaround times and workflows
As shown in Figure 2 , the three MALDI-TOF-based techniques were able to give a definitive result in a better turnaround time compared with the RAPIDEC V R CARBA NP in the case of non-CPE. Overall, these final results were obtained in 40 min, 55 min, 80 min and 150 min for the Brest in-house method, the MBT STAR V R -Carba IVD Kit, the Colmar in-house method and the RAPIDEC V R CARBA NP, respectively. However, in the case of CPE, the RAPIDEC V R CARBA NP is able to give results in an intermediate turnaround time. Here, the test was checked after 5, 15, 30, 60 and 120 min of incubation following the first lysis step (30 min) (Figure 2 and Tables S1-S4). Using this strain collection, positive results were obtained after: (i) 35 min total time for KPC, NDM, IMP and GIM producers; (ii) 45 min total time for VIM producers and non-KPC Ambler class A carbapenemase producers; and (iii) 90 min for most of the OXA-48-like producers. Only carbapenemase enzymes with very weak activity (OXA-232, OXA-244 and GES-5) needed complete incubation for a total time of 150 min.
The technical handling time for one bacterial isolate, which is associated with an additional technical staff cost (not estimated here), is 10 min for the two in-house MALDI-TOF techniques, 15 min for the MBT STAR V R -Carba IVD Kit and 2 min for the RAPIDEC V R CARBA NP (Figure 2 ).
Discussion
During the last decade, MALDI-TOF MS has become the workhorse for the identification of bacterial isolates. Although the use of MALDI-TOF detection of carbapenemases JAC MALDI-TOF technology has drastically changed the landscape of bacterial identification in clinical laboratories, very few other applications are currently proposed on commercially available machines. One of the most promising tools that has been recently developed on MALDI-TOF MS is the detection of antimicrobial resistance and particularly the detection of carbapenemase hydrolytic activity. The first MALDI-TOF-based detection method for the identification of CPE was developed in 2011. 37, 38 Since then several teams have developed similar in-house techniques in which the incubation time, the carbapenem and the type of mass spectrometer used vary. 27 Thus, these in-house techniques are sometimes difficult to reproduce in another centre. Recently, a CE-IVD MALDI-TOF-based detection method for the identification of CPE has been developed and commercialized, the MBT STAR V R -Carba IVD Kit. Here, we have evaluated this first commercially available test in comparison with in-house assays developed on the two most widespread mass spectrometers, the Microflex LT Biotyper (Bruker Daltonics) and the VITEK V R MS Plus (bioMérieux). This blinded evaluation revealed that the MBT STAR V R -Carba IVD Kit possesses excellent performance for the accurate detection of CPE among Enterobacteriaceae with decreased susceptibility to carbapenems (Table S1 ). Overall, the performance of this test was similar to the performance of the two other in-house techniques and to the RAPIDEC V R CARBA NP, another commercially available test dedicated to the early detection of carbapenem-hydrolysing activity in Gram-negative bacteria. 24, 26 The MBT STAR V R -Carba IVD Kit seems to be adapted to the routine workflow of clinical microbiology laboratories. Indeed, among the three MALDI-TOF-based techniques, MBT STAR V R -Carba IVD Kit shares the best turnaround time with the Brest in-house technique, which allows final results to be obtained in ,1 h (40 min for the Brest in-house technique and 55 min for the MBT STAR V R -Carba IVD Kit). This reduced turnaround time is an improvement compared with the in-house technique of Colmar (80 min), but also compared with the RAPIDEC V R CARBA NP, which is able to give a definitive result in only 150 min. However, it should be mentioned that, as opposed to all the MALDI-TOF-based techniques, the RAPIDEC V R CARBA NP turnaround time could be reduced to 35 min total time for KPC, NDM, IMP and GIM producers, 45 min total time for VIM producers and non-KPC Ambler class A carbapenemase producers and 60 min for most of the OXA-48-like producers (Figure 2) . The technical handling time is 10 min and 15 min for the two in-house MALDI-TOF techniques and the MBT STAR V R -Carba IVD Kit, respectively. The sample preparation is slightly more time consuming than the RAPIDEC V R CARBA (Table S1 ).
b Strain numbers 155 and 162 not detected as CPE (Table S3 ). c Strain numbers 32, 33, 67 and 85 not detected as CPE (Table S4) .
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NP (2 min of technical handling time), which also does not require any additional equipment (centrifuge, microtubes) as compared with the MALDI-TOF-based techniques. However, for the MBT STAR V R -Carba IVD Kit, the automated interpretation of the result avoids any subjective analysis of the results, which has been reported to sometimes be tricky with the RAPIDEC V R CARBA NP in the presence of OXA-48-like-producing Enterobacteriaceae. 33 The MBT STAR V R -Carba IVD Kit is also the only technique able to provide a concomitant identification of the bacterial isolate. As expected for a CE-IVD kit, we also demonstrated excellent repeatability of the MBT STAR V R -Carba IVD Kit, which is crucial for its implementation into routine use. Another main advantage of the MBT STAR V RCarba IVD Kit coupled with the MBT STAR V R -BL IVD software is the possible direct connection with laboratory software, which limits the technical errors that can occur when copying data, and also contributes to a fast turnaround time.
Overall, our results demonstrate that the MBT STAR V R -Carba IVD Kit is a reliable technique for the rapid detection of CPE that possesses all the required properties to be implemented in a clinical microbiology laboratory that is already equipped with a Microflex LT Biotyper (Bruker Daltonics) mass spectrometer. Finally, based on the few publications that mixed an in-house MALDI-TOF technique with the use of known inhibitors of Ambler class A enzymes (e.g. tazobactam, clavulanic acid or boronic acid) and metallo-b-lactamases (e.g. EDTA and dipicolinic acid), [39] [40] [41] we might expect future development of the MBT STAR V R -Carba IVD Kit for not only detection of CPE but also classification of the carbapenemase produced. Indeed, this added function might be of the utmost interest for the management of infected patients with the development and the recent commercialization of a few therapies involving combinations of a broad-spectrum b-lactam and a b-lactamase inhibitor (e.g. ceftazidime/avibactam) that are only active against a few classes of carbapenemases (e.g. avibactam inhibits Ambler class A and D carbapenemases but not MBLs).
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